A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Active, not recruiting · Phase 3 · NCT06948422
Conditions: Hypertension
At a glance
- Research payments reported, 2025
- $172,481
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 974
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Orforglipron (drug), Placebo (drug)
- Dates
- Started 2025-04-30; completion 2027-09
- Results posted
- Not yet
The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.
From ClinicalTrials.gov, last updated 2026-05-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly Export S.a. Puerto Rico Branch reported $172,481 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Hr Services and Distributors Inc $172,481
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.